State-imported drugs would not affect 340B drug prices

Modern Healthcare: Drugs imported by states under the Trump administration's importation plan will not be subject to Medicaid rebates, which means they would not set new 340B prices according to CMS guidance released Friday.

The state guidance calls into question whether states will be able to save significant amounts of money through Medicaid buying imported drugs compared with the large statutory rebates already conferred by the Medicaid rebate program. The Medicaid rebate program also determines 340B ceiling prices, so any potential state importation programs would be excluded from factoring into those prices.

Read article

Share